

**NOW FDA approved for
MANIA IN BIPOLAR DISORDER**

**Well
Accepted!**

Another great reason to prescribe

- **Effective** so patients improve¹⁻³
- **Trusted tolerability** so patients can stay on treatment^{1,4,5}

The safety and efficacy of SEROQUEL in pediatric patients have not been established.

Patients should be periodically reassessed to determine the need for continued treatment.

Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.


There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL.

The most common adverse events associated with the use of SEROQUEL were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia, and weight gain.

In bipolar mania trials, withdrawal rates due to adverse events were similar to placebo for SEROQUEL as monotherapy (SEROQUEL 5.7%, placebo 5.1%) and adjunct therapy (SEROQUEL plus lithium or divalproex 3.6%, lithium or divalproex alone 5.9%).

References: 1. SEROQUEL® (quetiapine fumarate) Prescribing Information, Rev 01/04, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.

2. Data on file, DA-SER-13, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 3. Data on file, DA-SER-15, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 4. Data on file, DA-SER-14, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 5. Data on file, DA-SER-16, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.

 **Seroquel**[®]
quetiapine fumarate
25 mg, 100 mg, 200 mg & 300 mg tablets

AstraZeneca
AstraZeneca Pharmaceuticals LP
217350 1/04

To prevent medication errors, write "SEROQUEL" clearly on your Rx pad. Spell "SEROQUEL" clearly over the phone.

Please see Brief Summary of Prescribing Information on following page.

First-line treatment

www.SEROQUEL.com

© 2004 AstraZeneca Pharmaceuticals LP. All rights reserved. SEROQUEL is a registered trademark of the AstraZeneca group of companies.

<https://doi.org/10.1017/S1092852900002704> Published online by Cambridge University Press